Background: Studies have reported that advanced NSCLC benefits from celecoxib
combined with systematic treatment. However, the optimal combination with different …

Background The clinical benefit of a selective cyclooxygenase-2 inhibitor, celecoxib,
combined with anticancer therapy in advanced non-small-cell lung cancer (NSCLC) remains …

Aims Clinical trials have reported conflicting results about whether celecoxib plus
chemotherapy improves outcomes over chemotherapy alone in patients with advanced non …

Background and objective Currently, platinum-based regimes are standard first-line
chemotherapy for non-small cell lung cancer. The aim of this study is to evaluate the efficacy …

Abstract Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …

8005 Background: Cox-2 is overexpressed in NSCLC tumors and has a negative impact on
survival. It is involved in proliferation and angiogenesis. The hypothesis is that celecoxib by …

Purpose: Preclinical findings suggest that adding targeted therapies to combination
radiation-chemotherapy can enhance treatment efficacy; however, this approach may …

Introduction To evaluate the efficacy and toxicity of the combination of celecoxib and
docetaxel in patients with advanced non-small cell lung cancer after failure of platinum …

7339 Background: This phase I/II trial is being conducted to test the safety, toxicity, and initial
efficacy of this novel regimen of celecoxib plus carboplatin/gemcitabine for advanced …

Results Between November 2011 and August 2015, a total of 100 patients were initially
accrued, with 51 in Arm A and 45 in Arm B being eligible. There were no significant baseline …